ACTRN12620001153909尚未招募2 期
A Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL 514 Injectionon Thigh Subcutaneous Fat in healthy adults
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 64 Years（—）
- 性别
- All
入选标准
- •To be eligible for this study, a subject must meet all of the following inclusion criteria:
- •1.Male or female, aged 18 years to 64 years old (at Screening), inclusive.
- •2.Body mass index (BMI) >18.5 and <32 kg/m2 and body weight great than or equal to 50 kg at Screening and Day 1.
- •3.Subject has sufficient thigh subcutaneous fat thickness of at least 1.50 cm and up to 5.00 cm measured by ultrasound, surrounding the center of treatment area at Screening and Day 1.
- •4.Subject has stable body weight (identified as smaller than or equal to 5% weight change) for at least 3 months before Screening and during the study.
- •5.Subject who has maintained a stable lifestyle (e.g. exercise, eating patterns, and smoking habit) for at least 3 months before Screening and during the study.
- •6.Voluntarily signs the Informed Consent Form (ICF) and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
排除标准
- •A subject who meets any of the following exclusion criteria must be excluded from the study:
- •1.Female subject of childbearing potential who is not willing to commit to an acceptable contraceptive regimen with her partner from the time of Screening and throughout study participation until 90 days after the last IP dose, or who is currently pregnant or lactating. Male subject who is not willing to commit to an acceptable contraceptive method.
- •Females who have been surgically sterilized (hysterectomy or bilateral oophorectomy) or who are post-menopausal (e.g., defined as at least 50 years with greater than or equal to 12 months of amenorrhea with a FSH >40 IU/L) are considered to be of non-childbearing potential. Subjects who are not of childbearing potential are not required to use contraception.
- •2.Subject diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede coagulation or platelet aggregation.
- •3.Subject has fasting hemoglobin A1c (HbA1c) great than or equal to 7%.
- •4.Subject has a clinically significant cardiovascular disease and abnormal findings in electrocardiogram (ECG).
- •5.Subject with active or prior history of malignancies within 5 years before Screening or being worked-up for a possible malignancy. Except adequately treated basal cell carcinoma of skin and in situ squamous cell carcinoma of skin would be eligible as per Investigator’s discretion.
- •6.Subject with a history of human immunodeficiency virus (HIV)-1, infection or subjects with active HIV infection at Screening with positive HIV antigen/antibody (Ag/Ab) combo test.
- •7.Subjects with any hepatic medical condition that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide informed consent.
- •8.Subject has abnormal skin or local skin conditions at the treatment area, which in the opinion of Investigator, is inappropriate to participate in the study, including but not limited to any of the following:
- •a.Skin manifestations of a systemic disease,
- •b.Any abnormality of the skin or soft tissues of the area to be treated,
- •c.Grade III cellulite (Nürnberger and Muller scale, Nürnberger F, 1978) at the area to be treated,
- •d.Skin or superficial tissue that does not lie flat on its own when the subject is in the supine position,
- •e.Sensory loss or dysesthesia in the area to be treated,
- •f.Evidence of any cause of enlargement in the area to be treated other than localized subcutaneous fat,
- •g.Tattoos on the area to be treated.
- •9.Subject who has undergone the following procedures:
- •a.Previous surgery in the anticipated treatment area,
- •b.Metal implants of any type in the area to be treated,
- •c.Esthetic procedure i.e. liposuction to the region to be treated within 12 months before Screening or during the study,
- •d.Esthetic procedure e.g. cryolipolysis, ultrasonic lipolysis, low level laser therapy (LLLT), lipolysis injection to the region to be treated within 6 months before Screening or during the study.
- •10.Subject is on prescription or OTC weight reduction medication or weight reduction programs within 3 months before Screening or during the study.
- •11.Subject is undergoing chronic steroid or immunosuppressive therapy.
- •12.Requiring continual use of the following therapeutic agents during the study: S mephenytoin (Mesantoin), terfenadine (Teldane), buspirone (Buspar), fexofenadine (Fexotabs, Tef
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022155-33-DEGilead Sciences, Inc.120
进行中（未招募）
不适用
Efficacy and Safety of SM101 in the Treatment of IgA NephropathyIgA NephropathyMedDRA version: 18.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-002345-64-CZBaxalta Innovations GmbH51
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0 Level: PT Classification code 10029601 Term: Non-Hodgkin's lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022155-33-GBGilead Sciences, Inc.125
招募中
不适用
A Phase 2 Study to Assess the Efficacy and Safety of CMX-020 in Treating Osteoarthritis.osteoarthritisACTRN12616001435471Cytometix A90
进行中（未招募）
不适用
A Phase 2 Study of CAL-101 in Indolent B-Cell Non-Hodgkin LymphomaEUCTR2010-022155-33-ITCALISTOGA PHARMACEUTICALS, INC.120